Markets
Wall Street Trader Trump Picture Red Hat
(Spencer Platt/Getty Images)

Analyst: “A bull market in uncertainty”

“This too shall pass, at which point markets will rebound.”

With stocks whipsawing on Wednesday, Scott Clemons, partner and chief investment strategist at the venerable Wall Street firm Brown Brothers Harriman, took a few minutes to chat about the wild week since President Trump has unleashed the tariffs.

Shortly after our chat, Trump appeared to announce a partial pause on tariffs for some countries, while simultaneously unleashing a still higher levy of 125% on China “effective immediately.” Stocks exploded in response, with the S&P 500 up 6% in the immediate aftermath of the announcement and shares of some Trump-related stocks like Tesla up more than 10% at moments. Other megacap tech stocks like Apple and Nvidia were also up more than 10%.

Relief rally aside, for Clemons, the key question is what lasting impact the White House’s erratic, and what some Trump supporters describe as destructive, approach to managing the economy will have.

Here are highlights, edited for clarity and concision.

Sherwood News: So, what’s the mood out there among investors?

This is what I’m hearing from clients: right now, it’s all about the tariff tantrum. But even if that were to go away and be suspended or be lifted or whatever it is, what’s left is the crisis of competence.

What might next week bring? This week it’s tariffs; next week it’s some regulatory decision. That unpredictability and uncertainty is paralyzing business decisions.

And it’s paralyzing for consumer decisions, as well. Think about a family deciding, maybe we don’t need to take that vacation, buy the new car, renovate the kitchen. When you aggregate all of those things up, that is the recipe for a recession.

I believe we’re going to see in the second quarter a real drag on the real economy as businesses delay spending, they delay hiring, and they delay investments simply because of the uncertainty and the anxiety.

SN: From an investment perspective, the markets have done well during economic downturns in the past. Do you think that could play out this time?

This too shall pass, at which point markets will rebound. What I’m interested in as an economist and an investor is what is the lasting ripple effect from the uncertainty that remains behind? That, I think, could be a real break on both investing and on the economy for some time to come.

SN: Are there any particular sectors or markets where youre looking to see evidence of that lasting impact?

We’re going to get a real good insight to that starting tomorrow, when we get first-quarter earnings reports. Actual first-quarter earnings are so ancient history, they’re almost irrelevant.

But how companies talk about their positioning in this uncertainty is going to be interesting. So, I’m listening for companies talking about delayed hiring plans or delayed expansion plans, or, of course, how they’re dealing with the pricing uncertainty that tariffs bring.

There’s a bull market in uncertainty, at least, if there’s not a bull market in anything else.

More Markets

See all Markets
markets

FuelCell Energy rises as AI data center pipeline overshadows Q2 miss

FuelCell Energy shares rebounded into positive territory during premarket trading, reversing an initial dip sparked by Q2 results that showed widening net losses and a year-over-year revenue decline.

Key numbers:

  • Revenue of $35.6 million (compared to analyst estimates of $40.56 million).

  • An adjusted loss per share of $1.45 (estimate: a $0.50 loss).

That revenue number marks a 5% decrease from the $37.4 million generated during the same quarter last year.

The company’s net loss expanded to $78.7 million, or $1.45 per share, compared to a loss of $38.8 million in the prior-year period. Management attributed the deeper loss primarily to a $42.6 million one-time impairment expense linked to essential equipment upgrades at its Groton Project facility.

While a 9.9% drop in total backlog initially added to the shares’ downward momentum, investors appeared to quickly pivot their attention to the company’s forward-looking metrics. FuelCell highlighted a 267% sequential jump in its sales pipeline, which has reached 4 gigawatts. The surge is driven by demand for its packaged 12.5-megawatt utility-grade power block solution tailored specifically for the booming AI data center market.

To support this high-growth data center strategy, FuelCell announced a major capacity expansion at its Torrington, Connecticut, manufacturing facility. The company plans to raise its annualized production ceiling from 350 MW to 500 MW, an infrastructure upgrade estimated to cost between $200 million and $275 million over the next 24 months.

Driven by the AI data center narrative, FuelCell Energy’s stock has risen over 130% year to date.

markets

Lilly says its next-gen GLP-1 shot drove 28.3% weight loss, reduced comorbidities

Eli Lilly has risen around 4% in premarket trading after reporting impressive trial results for its next-generation weight-loss drug over the weekend.

According to the results unveiled on Saturday, Lilly’s experimental weight-loss shot, retatrutide, helped patients lose 28.3% of their body weight at 80 weeks. That’s more than tirzepatide, Lilly’s weight-loss shot currently considered the most effective in the market, which helped people lose 26% of their weight over 88 weeks.

Retatrutide is a triple agonist, meaning it mimics three different hormones that promote weight loss, compared to one by Novo Nordisk’s semaglutide and two by tirzepatide. Lilly says it helps preserve more muscle mass than other weight-loss shots and also helped improve knee osteoarthritis pain and obstructive sleep apnea.

Lilly has said it would submit the drug for approval this year with the goal of getting it out to market in 2027. The jab could be the next big moneymaker for Lilly, which currently sells the most lucrative drug in the world but has had an underwhelming rollout of its oral weight-loss pill, which came to market earlier this year.

Retatrutide is already quite popular among those who experiment with peptides, or unapproved injectable drugs often sold online “for research purposes only.” For gym bros trying to attain a certain physique, a drug that has shown it can melt fat while preserving muscle is enticing.

But in a market full of knockoff drugs, will retatrutide enthusiasts pay full price for the drug when it officially goes to market?

markets

Marvell and Flex rise on S&P 500 inclusion announcement

Chipmaker Marvell Technology and electronics manufacturer Flex are jumping 7% and 3%, respectively, in premarket trading on Monday after S&P Dow Jones Indices announced late on Friday that the two companies are set to join the S&P 500 benchmark index.

Replacing Pool Corp. and Campbell’s in the S&P 500, Marvell and Flex’s addition will be effective from June 22, per a press release from the provider, which assesses and updates the index on a quarterly basis.

Marvell has been one of the leading candidates for inclusion across the last few quarterly index rebalances. The company has ballooned into a $230 billion chip giant of late, thanks to the wider AI boom, investors chasing momentum, and, yes, Jensen Huang. Flex, which has been part of the S&P MidCap 400 Index since 2024, has also grown recently, having played a part in the data center boom with a portfolio that spans across infrastructure and cooling systems.

With today’s premarket movement taken into account, MRVL has now risen almost 40% in the last week alone.

Dickens, Great Expectations, He said, Aha! would you?

Tech tumbles as momentum stocks run into a blowout jobs report and a wave of profit-taking

The AI trade is under some pressure, taking prices back like... a few days. President Donald Trump is not a fan of the price action.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.